April 25, 2017 7:52 AM ET

Pharmaceuticals

Company Overview of kaleo, Inc.

Company Overview

kaleo, Inc. develops, markets, and sells pharmaceutical and medical products. The company offers drug and device development and human factors engineering (HFE) services. kaleo, Inc. was formerly known as Intelliject, Inc. and changed its name to kaleo, Inc. in January 2014. The company was founded in 2008 and is based in Richmond, Virginia.

111 Virginia Street

Suite 300

Richmond, VA 23219

United States

Founded in 2008

Phone:

804-545-6360

Fax:

804-545-6219

Key Executives for kaleo, Inc.

Chief Executive Officer, President and Director
Co-founder and Vice President of Product Development
Chief Financial Officer
Age: 49
Chief Operating Officer
Age: 55
Vice President and General Counsel
Compensation as of Fiscal Year 2016.

kaleo, Inc. Key Developments

Kaleo, Inc. Announces Availability of New Auto-Injector for Allergic Reactions

kaleo, Inc. has announced the AUVI-Q (epinephrine injection, USP) auto-injector, indicated to treat life-threatening allergic reactions, will be available by prescription, effective February 14, 2017. In addition, the company has announced AUVI-Q Affordability, an access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q. AUVI-Q is a FDA-approved prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. It is an epinephrine auto-injector with innovative features such as voice instructions that help guide a user with step-by-step instructions through the epinephrine delivery process and an automatic retractable needle system, a first for epinephrine auto-injectors, that injects the epinephrine and retracts the needle back into the device within seconds. This new program removes potential and previously experienced insurance barriers, restrictions and delays, even for those commercially-insured patients with high-deductible plans. AUVI-Q will also be available via a direct delivery service, that can ensure the best expiration dating for AUVI-Q.

sanofi-aventis U.S. LLC. Signs License and Development Agreement with kaleo, Inc

sanofi-aventis U.S. LLC. has signed a license and development agreement with kaleo, Inc. (formerly Intelliject, Inc.), a pharmaceutical company that provides solutions for serious and life-threatening medical conditions, for the auto-injector Auvi-Q(R). Auvi-Q is used to treat life-threatening allergic reactions (anaphylaxis).

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact kaleo, Inc., please visit www.kaleopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.